GlassScriptPhysician profile
Jai Varma
NPI 1952520488
$12,651.30
in general payments reported to CMS, 2019-2025
46 companies · $1,590 in 2025
The $1,590 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,231 · 2020: $2,049 · 2021: $2,288 · 2022: $1,786 · 2023: $1,297 · 2024: $1,411 · 2025: $1,590.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,298.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,297.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,754.45 | 2019-2025 | |
| Abbott Laboratories | $1,254.40 | 2019-2025 | Aveir, Optis, Gallant |
| Janssen Pharmaceuticals, INC | $1,148.43 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $829.97 | 2019-2022 | |
| Amgen INC. | $765.12 | 2019-2025 | Repatha |
| Amarin Pharma, INC. | $711.09 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $648.90 | 2021-2025 | Verquvo |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $643.72 | 2019-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $612.54 | 2019-2025 | Eliquis, Camzyos |
| Novo Nordisk INC | $496.84 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $482.52 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $375.12 | 2019-2025 | Jardiance |
| Heartflow, INC. | $362.30 | 2019-2024 | Ffrct |
| Esperion Therapeutics, INC. | $246.84 | 2020-2024 | Nexletol |
| Astellas Pharma US INC | $241.79 | 2019-2020 |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $240.81 | 2023-2025 | (9520) Igt Devices Undivided, Coronary Other |
| Edwards Lifesciences Corporation | $181.36 | 2024 | |
| Boston Scientific Corporation | $180.05 | 2020-2023 | |
| Abiomed | $148.56 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $131.63 | 2019-2025 | Evkeeza, Praluent |
| Kiniksa Pharmaceuticals International, Plc | $123.94 | 2024 | Arcalyst |
| Medtronic, INC. | $110.51 | 2024 | Onyx Frontier |
| Vifor Pharma, INC. | $103.53 | 2020-2021 | |
| Biotronik INC. | $102.03 | 2024 | Orsiro Mission |
| Arbor Pharmaceuticals, INC. | $95.97 | 2019-2022 | |
| Alnylam Pharmaceuticals INC. | $91.59 | 2022-2025 | Amvuttra, Onpattro |
| Althera Pharmaceuticals LLC | $63.53 | 2021-2022 | |
| Itamar Medical INC | $51.16 | 2022-2025 | Watchpatone |
| Acist Medical Systems, INC. | $48.35 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $41.62 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $41.49 | 2019-2023 | |
| Gilead Sciences, INC. | $37.11 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $36.58 | 2025 | |
| Inspire Medical Systems, INC. | $36.44 | 2025 | Inspire |
| Genzyme Corporation | $35.03 | 2022 | |
| Myocardial Solutions, INC. | $28.94 | 2021 | |
| Shockwave Medical, INC | $28.67 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Inari Medical, INC. | $27.55 | 2019 | |
| Cvrx, INC. | $19.48 | 2024 | Barostim Neo System |
| Angiodynamics, INC. | $17.22 | 2022 | |
| Surmodics, INC. | $16.58 | 2022 | |
| Cathworks, INC. | $14.06 | 2025 | Ffrangio |
| Elutia, INC. | $10.67 | 2019 | |
| Bardy Diagnostics, INC. | $8.50 | 2019 | |
| Cardiovascular Systems INC. | $4.31 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$649,779.74 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jai Varma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.